Biogen’s Alzheimer’s drug is unlikely to get EU approval.

Pharmaceutical manufacturer Biogen said on Wednesday The latest setback for a controversial drug since it was approved in the United States in June, when a drug review panel in the European Union said the new Alzheimer’s drug is unlikely to be approved there. Biogen said a committee of experts advising the European Medicines Agency issued …

Sales of Biogen’s expensive new Alzheimer’s drug lag far behind

Pharmaceutical manufacturer Biogen reported On Wednesday, the new Alzheimer’s drug, Aduhelm, brought in $300,000 from July to September, well below the company’s targets and Wall Street expectations. The sales figures Biogen announced in its third-quarter financial report, the drug’s first period of full availability, represented a rather slow start for a treatment that was promoted …

Biogen’s Aduhelm Sales Total $2 Million in the Second Quarter

Pharmaceutical manufacturer Biogen reported its on thursday Controversial Alzheimer’s drug aduhelm It brought in $2 million in its first few weeks, which is the first revenue for a treatment that is expected to generate billions of dollars in a few years and strain Medicare’s budget. The company did not disclose the number of patients who …